JP2015212268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015212268A5 JP2015212268A5 JP2015113215A JP2015113215A JP2015212268A5 JP 2015212268 A5 JP2015212268 A5 JP 2015212268A5 JP 2015113215 A JP2015113215 A JP 2015113215A JP 2015113215 A JP2015113215 A JP 2015113215A JP 2015212268 A5 JP2015212268 A5 JP 2015212268A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- days
- cytarabine
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 86
- 229960000684 cytarabine Drugs 0.000 claims 86
- 150000001875 compounds Chemical class 0.000 claims 33
- 239000003814 drug Substances 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 208000032839 leukemia Diseases 0.000 claims 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 5
- 229960000975 daunorubicin Drugs 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 4
- 229960005420 etoposide Drugs 0.000 claims 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 229960002756 azacitidine Drugs 0.000 claims 3
- 206010066476 Haematological malignancy Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20264709P | 2009-03-23 | 2009-03-23 | |
| US61/202,647 | 2009-03-23 | ||
| US17380309P | 2009-04-29 | 2009-04-29 | |
| US61/173,803 | 2009-04-29 | ||
| US26698909P | 2009-12-04 | 2009-12-04 | |
| US61/266,989 | 2009-12-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502141A Division JP6033678B2 (ja) | 2009-03-23 | 2010-03-22 | 併用療法を用いた治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015212268A JP2015212268A (ja) | 2015-11-26 |
| JP2015212268A5 true JP2015212268A5 (enExample) | 2016-02-12 |
Family
ID=42173409
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502141A Active JP6033678B2 (ja) | 2009-03-23 | 2010-03-22 | 併用療法を用いた治療方法 |
| JP2015113215A Pending JP2015212268A (ja) | 2009-03-23 | 2015-06-03 | 併用療法を用いた治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502141A Active JP6033678B2 (ja) | 2009-03-23 | 2010-03-22 | 併用療法を用いた治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8357690B2 (enExample) |
| EP (1) | EP2410987B1 (enExample) |
| JP (2) | JP6033678B2 (enExample) |
| KR (1) | KR101755725B1 (enExample) |
| CN (1) | CN102438588B (enExample) |
| AU (1) | AU2010228982B2 (enExample) |
| BR (1) | BRPI1013698A2 (enExample) |
| CA (1) | CA2755976C (enExample) |
| ES (1) | ES2681529T3 (enExample) |
| FR (1) | FR24C1013I2 (enExample) |
| IL (1) | IL215131A (enExample) |
| MX (1) | MX2011009989A (enExample) |
| NZ (1) | NZ595382A (enExample) |
| RU (1) | RU2543348C2 (enExample) |
| SG (1) | SG174419A1 (enExample) |
| WO (1) | WO2010111172A1 (enExample) |
| ZA (1) | ZA201106730B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145070A (en) * | 2006-03-17 | 2011-12-15 | Ambit Biosciences Corp | Imidazolothiazole compounds for the treatment of disease |
| WO2010111172A1 (en) * | 2009-03-23 | 2010-09-30 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| SMT202000092T1 (it) | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| AU2012321106C1 (en) * | 2011-11-03 | 2016-11-24 | Takeda Pharmaceutical Company Limited | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent |
| CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
| JP6116847B2 (ja) | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| EP2928456B1 (en) * | 2012-12-07 | 2021-02-03 | Onconova Therapeutics, Inc. | Treatment of hematological cancer refractory to an anti-cancer agent |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| JP6529138B2 (ja) * | 2013-09-13 | 2019-06-12 | ウェスタン ユニバーシティ オブ ヘルス サイエンス | 化学療法耐性を克服するためのウィルホルリドａの使用 |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| EP3260119B1 (en) * | 2015-02-20 | 2023-11-15 | Daiichi Sankyo Company, Limited | Combination method for treating cancer |
| WO2017010382A1 (ja) * | 2015-07-14 | 2017-01-19 | 国立大学法人大阪大学 | 筋強直性ジストロフィー治療薬 |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CA3014530A1 (en) | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| JP6856657B2 (ja) * | 2016-02-26 | 2021-04-07 | アジオス ファーマシューティカルズ， インコーポレイテッド | 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤 |
| JP7082263B2 (ja) | 2016-03-15 | 2022-06-08 | オリソン ヘノミクス エセ． アー． | 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| US20210292410A1 (en) | 2017-12-07 | 2021-09-23 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| WO2020171646A1 (ko) | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물 |
| TW202045174A (zh) | 2019-02-28 | 2020-12-16 | 日商富士軟片股份有限公司 | 組合醫藥 |
| JP2022538817A (ja) * | 2019-06-27 | 2022-09-06 | ハンミ ファーマシューティカル カンパニー リミテッド | Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物 |
| KR102694140B1 (ko) * | 2020-12-31 | 2024-08-12 | 울산대학교 산학협력단 | 소라페닙의 간암에 대한 활성 증진용 조성물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1050899A (enExample) | 1963-12-22 | |||
| DE2012888C3 (de) | 1970-03-14 | 1981-04-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4751221A (en) | 1985-10-18 | 1988-06-14 | Sloan-Kettering Institute For Cancer Research | 2-fluoro-arabinofuranosyl purine nucleosides |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5384310A (en) | 1989-05-23 | 1995-01-24 | Southern Research Institute | 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| EP0816366A4 (en) * | 1995-03-13 | 1998-07-08 | Nikken Chemicals Co Ltd | IMIDAZOTHIAZOLE COMPOUNDS |
| WO2002076439A2 (en) * | 2001-03-23 | 2002-10-03 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
| EP1412369B1 (en) | 2001-08-02 | 2008-05-07 | Ilex Oncology, Inc. | Process for preparing purine nucleosides |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US20070006613A1 (en) | 2005-06-20 | 2007-01-11 | Hirsch Victoria H | Coil beaded fashion accessory with attached key ring |
| MY145070A (en) * | 2006-03-17 | 2011-12-15 | Ambit Biosciences Corp | Imidazolothiazole compounds for the treatment of disease |
| WO2008028193A2 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| CN101868465B (zh) | 2007-09-19 | 2013-12-25 | 埃姆比特生物科学公司 | 包含N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲的固体形式、其组合物及其应用 |
| AU2008325141B2 (en) | 2007-11-08 | 2014-03-20 | Ambit Biosciences Corp. | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| WO2010054058A1 (en) | 2008-11-06 | 2010-05-14 | Ambit Bioscience Corporation | Imidazolothiazole compounds as modulators of protein kinase |
| WO2010111172A1 (en) * | 2009-03-23 | 2010-09-30 | Ambit Biosciences Corporation | Methods of treatment using combination therapy |
| SMT202000092T1 (it) | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| CN102639539B (zh) | 2009-11-05 | 2014-12-10 | 埃姆比特生物科学公司 | 用于制备咪唑并[2，1-b][1，3]苯并噻唑衍生物的方法 |
-
2010
- 2010-03-22 WO PCT/US2010/028129 patent/WO2010111172A1/en not_active Ceased
- 2010-03-22 MX MX2011009989A patent/MX2011009989A/es active IP Right Grant
- 2010-03-22 KR KR1020117024766A patent/KR101755725B1/ko active Active
- 2010-03-22 NZ NZ595382A patent/NZ595382A/en unknown
- 2010-03-22 SG SG2011066677A patent/SG174419A1/en unknown
- 2010-03-22 RU RU2011142750/15A patent/RU2543348C2/ru active
- 2010-03-22 CN CN201080022606.5A patent/CN102438588B/zh active Active
- 2010-03-22 ES ES10710144.6T patent/ES2681529T3/es active Active
- 2010-03-22 JP JP2012502141A patent/JP6033678B2/ja active Active
- 2010-03-22 EP EP10710144.6A patent/EP2410987B1/en active Active
- 2010-03-22 BR BRPI1013698A patent/BRPI1013698A2/pt not_active Application Discontinuation
- 2010-03-22 AU AU2010228982A patent/AU2010228982B2/en active Active
- 2010-03-22 CA CA2755976A patent/CA2755976C/en active Active
- 2010-03-23 US US12/730,097 patent/US8357690B2/en active Active
-
2011
- 2011-09-13 IL IL215131A patent/IL215131A/en active IP Right Grant
- 2011-09-14 ZA ZA2011/06730A patent/ZA201106730B/en unknown
-
2013
- 2013-01-18 US US13/745,680 patent/US8836218B2/en active Active
-
2015
- 2015-06-03 JP JP2015113215A patent/JP2015212268A/ja active Pending
-
2024
- 2024-04-04 FR FR24C1013C patent/FR24C1013I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015212268A5 (enExample) | ||
| JP2012521435A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2020033360A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2013533858A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2013121983A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2017503014A5 (enExample) | ||
| JP2012522837A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2016527202A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| JP2016531885A5 (enExample) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| RU2010151660A (ru) | Способы лечения множественной миеломы | |
| JP2008514577A5 (enExample) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2015507020A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| JP2020515523A5 (enExample) | ||
| JP2018506533A5 (enExample) | ||
| JP2017514858A5 (enExample) |